Leerink Partners Downgrades CureVac to Market Perform, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mani Foroohar downgrades CureVac (NASDAQ:CVAC) from Outperform to Market Perform and lowers the price target from $12 to $4.

April 25, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CureVac was downgraded by Leerink Partners from Outperform to Market Perform, with a significant reduction in price target from $12 to $4.
The downgrade by a notable analyst firm, Leerink Partners, from Outperform to Market Perform, coupled with a substantial decrease in the price target, is likely to negatively impact investor sentiment and the short-term stock price of CureVac. Such analyst actions often lead to immediate market reactions, as they may reflect changes in the company's outlook or market position.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100